Health Trials

Cancer Harboring BRAF Alterations

1

Review clinical trials related to Cancer Harboring BRAF Alterations. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.

Participants needed: 254
Trial details
Phase: Phase 2Age: 8+Biological sex: AllType: InterventionalSponsor: Fore BiotherapeuticsUpdated: Jul 27, 2026Locations: 70
Eligibility criteria

Male and female, ≥8 years of age, and weighing ≥25 kg. [+30]

Prior treatment with RAF/BRAF inhibitors active for Class 2 BRAF alterations for... [+30]

Read more